Wuhan Hiteck Biological Pharma Enters Into Exclusive License Agreement With NovaBridge’s Visara For HT006.2.2, Investigational Next-Gen Modified rhNGF Eye Drop

Loading news article.

Wuhan Hiteck Biological Pharma Enters Into Exclusive License Agreement With NovaBridge’s Visara For HT006.2.2, Investigational Next-Gen Modified rhNGF Eye Drop | WAPE

Wuhan Hiteck Biological Pharma Enters Into Exclusive License Agreement With NovaBridge’s Visara For HT006.2.2, Investigational Next-Gen Modified rhNGF Eye Drop

Article summary

Related companies

Analyzed by WAPE AI.

Comments —